Home
/
Fulgent Genetics, Inc.
/
Financials
/
Quarterly
Fulgent Genetics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Fulgent Genetics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$5.63M
Nov 9, 2018
Q2
2018
Jun 30, 2018
$5.40M
Aug 13, 2018
Q1
2018
Mar 31, 2018
$4.65M
May 14, 2018
Q3
2018
Sep 30, 2017
$4.50M
Nov 9, 2018
Q2
2018
Jun 30, 2017
$4.64M
Aug 13, 2018
Q1
2018
Mar 31, 2017
$5.31M
May 14, 2018
Q3
2017
Sep 30, 2016
$5.01M
Nov 13, 2017
Q2
2017
Jun 30, 2016
$3.97M
Aug 14, 2017
Q1
2017
Mar 31, 2016
$3.44M
May 9, 2017
Q3
2016
Sep 30, 2015
$2.91M
Nov 14, 2016
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$84.07M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$81.80M
Aug 1, 2025
Q1
2025
Mar 31, 2025
$73.46M
May 2, 2025
Q3
2025
Sep 30, 2024
$71.74M
Nov 7, 2025
Q2
2025
Jun 30, 2024
$71.03M
Aug 1, 2025
Q1
2025
Mar 31, 2024
$64.49M
May 2, 2025
Q3
2024
Sep 30, 2023
$84.69M
Nov 8, 2024
Q2
2024
Jun 30, 2023
$67.85M
Aug 2, 2024
Q1
2024
Mar 31, 2023
$66.17M
May 3, 2024
Q3
2023
Sep 30, 2022
$105.66M
Nov 3, 2023
Q2
2023
Jun 30, 2022
$125.34M
Aug 4, 2023
Q1
2023
Mar 31, 2022
$320.27M
May 5, 2023
Q3
2022
Sep 30, 2021
$227.87M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$153.62M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$359.43M
May 5, 2022
Q3
2021
Sep 30, 2020
$101.72M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$17.27M
Aug 10, 2021
Q1
2021
Mar 31, 2020
$7.75M
May 7, 2021
Q3
2020
Sep 30, 2019
$10.35M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$8.42M
Aug 5, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($6.61M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($18.96M)
Aug 1, 2025
Q1
2025
Mar 31, 2025
($11.53M)
May 2, 2025
Q3
2025
Sep 30, 2024
($14.65M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($8.71M)
Aug 1, 2025
Q1
2025
Mar 31, 2024
($13.46M)
May 2, 2025
Q3
2024
Sep 30, 2023
($13.11M)
Nov 8, 2024
Q2
2024
Jun 30, 2023
($11.23M)
Aug 2, 2024
Q1
2024
Mar 31, 2023
($15.34M)
May 3, 2024
Q3
2023
Sep 30, 2022
$1.72M
Nov 3, 2023
Q2
2023
Jun 30, 2022
$11.54M
Aug 4, 2023
Q1
2023
Mar 31, 2022
$153.98M
May 5, 2023
Q3
2022
Sep 30, 2021
$122.52M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$79.81M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$200.69M
May 5, 2022
Q3
2021
Sep 30, 2020
$46.64M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$3.32M
Aug 10, 2021
Q3
2020
Jun 30, 2020
$3.32M
Nov 9, 2020
Q1
2021
Mar 31, 2020
($1.96M)
May 7, 2021
Q2
2020
Mar 31, 2020
($1.96M)
Aug 5, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($15.35M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($19.71M)
Aug 1, 2025
Q1
2025
Mar 31, 2025
($19.80M)
May 2, 2025
Q3
2025
Sep 30, 2024
($17.08M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($18.91M)
Aug 1, 2025
Q1
2025
Mar 31, 2024
($21.80M)
May 2, 2025
Q3
2024
Sep 30, 2023
$214.0K
Nov 8, 2024
Q2
2024
Jun 30, 2023
($19.80M)
Aug 2, 2024
Q1
2024
Mar 31, 2023
($24.82M)
May 3, 2024
Q3
2023
Sep 30, 2022
$352.0K
Nov 3, 2023
Q2
2023
Jun 30, 2022
$12.79M
Aug 4, 2023
Q1
2023
Mar 31, 2022
$201.93M
May 5, 2023
Q3
2022
Sep 30, 2021
$159.27M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$98.90M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$266.92M
May 5, 2022
Q3
2021
Sep 30, 2020
$63.52M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$2.64M
Aug 10, 2021
Q1
2021
Mar 31, 2020
($1.91M)
May 7, 2021
Q3
2020
Sep 30, 2019
$1.51M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$295.0K
Aug 5, 2020